New Clinical Advisory Board for PromarkerD global rollout

Proteomics International Laboratories Ltd  has assembled a team of world leading clinicians specialising in nephrology and endocrinology to advise the Company on its clinical and commercial initiatives towards a successful launch of the PromarkerD test for diabetic kidney disease to physicians globally.

The new advisory board offers doctors’ viewpoint in commercialisation of the PromarkerD blood test for the prediction of diabetic kidney disease. Doctors will ultimately order PromarkerD for diabetes patients with the advisory board able to provide specific and tailored advice from the voice of the customer perspective.

Clinical Advisory Board

ASX Release